JACK SCHULER - Corporate Board Profile

Accelerate Diagnostics, Inc

Filing Date	Source Excerpt
2012-05-17	Mr. Schuler, 71, is a founding partner of Crabtree Partners, a private equity investment firm. Mr. Schuler served as a director of Ventana Medical Systems, Inc. from 1991 and as Chairman of the Board from 1995 until Ventana’s acquisition by Roche in 2008. Mr. Schuler has been a director of Stericycle, Inc. (NASDAQ: SRCL) since March 1990, formerly serving as Chairman of the Board, and continues to serve as Lead Director for Stericyle. Prior to joining Stericycle, Inc., Mr. Schuler held various executive positions at Abbott Laboratories from December 1972 through August 1989, most recently serving as President and Chief Operating Officer. He is currently a director of Quidel Corporation (NASDAQ: QDEL) and Medtronic, Inc. (NYSE: MDT). Mr. Schuler holds a B.S. in Mechanical Engineering from Tufts University and an M.B.A. from Stanford University.
2012-11-13	Jack Schuler has served as a Director of the Company since June 26, 2012. ... Currently, Lawrence Mehren serves as the Company’s Chief Executive Officer and Jack Schuler serves as the Chairman of the Board. ... Jack Schuler and Matthew W. Strobeck, Ph.D., each independent directors, serve as members of our Audit Committee. ... The table below sets forth the compensation of our directors for serving as our directors for the fiscal year ended July 31, 2012: ... Jack Schuler fees earned or paid in cash: —, non-equity stock awards: —, option awards: —, total: —.
2013-11-05	Jack Schuler has served as a Director of the Company since June 26, 2012. Mr. Schuler is a founding partner of Crabtree Partners, a private equity investment firm.
2014-04-15	Jack Schuler 73 Director Jack Schuler 212,542 Includes annual award of option to purchase 44,670 shares of common stock at an exercise price of $6.48 per share, which vests in 12 equal monthly installments with the first installment vesting on May 3, 2013.
2015-04-08	Jack Schuler has served as a Director of the Company since June 26, 2012. Mr. Schuler is a founding partner of Crabtree Partners, a private equity investment firm. Mr. Schuler served as a director of Ventana Medical Systems, Inc. from 1991 and as Chairman of the Board from 1995 until Ventana’s acquisition by Roche in 2008. Mr. Schuler has been a director of Stericycle, Inc. (NASDAQ: SRCL) since March 1990, formerly serving as Chairman of the Board, and continues to serve as Lead Director for Stericyle. Prior to joining Stericycle, Inc., Mr. Schuler held various executive positions at Abbott Laboratories from December 1972 through August 1989, most recently serving as President and Chief Operating Officer. He is currently a director of Quidel Corporation (NASDAQ: QDEL) and Hansen Medical, Inc. (NASDAQ: HNSN). Mr. Schuler holds a B.S. in Mechanical Engineering from Tufts University and an M.B.A. from Stanford University.
2016-04-01	Jack Schuler 75 Director The Board maintains a standing Audit Committee comprised of Mr. ten Brink (Chairman), Mr. Schuler and Dr. Strobeck. The Board maintains a standing Compensation Committee comprised of Messrs. Miller, Patience, Schuler, Strobeck and ten Brink.
2017-04-10	Jack Schuler 76 Director ...The Board maintains a standing Audit Committee comprised of Mr. ten Brink (Chairman), Mr. Schuler and Dr. Strobeck. ...The Board maintains a standing Compensation Committee comprised of Messrs. Miller, Patience, Schuler, Strobeck and ten Brink. ...The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2016: Jack Schuler 79,519 79,519
2018-04-12	The Board maintains a standing Audit Committee comprised of Mr. ten Brink (Chairman), Mr. Schuler and Dr. Strobeck. Each member of the Audit Committee satisfies the independence standards specified in Rule 5605(a)(2) of the NASDAQ Listing Rules and the related rules of the SEC and has been determined by the Board to be “financially literate” with accounting or related financial management experience. The Board has also determined that Mr. ten Brink is an “audit committee financial expert” as defined under SEC rules and regulations, and qualifies as a financially sophisticated audit committee member as required under Rule 5605(c)(2)(A) of the NASDAQ Listing Rules. The Audit Committee has a written charter, a copy of which is available online at http://acceleratediagnostics.com/investors/corporate-governance/. The Audit Committee met 5 times during the year ended December 31, 2017. The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2017: Jack Schuler Option Award(1) ($) 161,802 Total ($) 161,802
2019-04-05	Jack Schuler has served as a Director of the Company since June 26, 2012. The Board maintains a standing Nominating and Governance Committee comprised of Messrs. Miller (Chairman) and Schuler and Dr. Watts. The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2018: Jack Schuler (7) 115,667(2) 115,667 As of December 31, 2018, Mr. Schuler held 43,283 options to purchase shares of our common stock.
2020-04-01	Jack Schuler has served as a Director of the Company since June 26, 2012. ... The Board maintains a standing Nominating and Governance Committee comprised of Messrs. Miller (Chairman), Diggelmann, Schuler and Dr. Watts. ... The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2019: Jack Schuler (10) Option Award (1) ($) 133,904 Total ($) 133,904
2021-04-05	Jack Schuler 80 Director... The Board has affirmatively determined that directors... Schuler... are independent directors... The Board maintains a standing Nominating and Governance Committee comprised of Messrs. Miller (Chairman), Diggelmann, Schuler and Dr. Watts... The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2020: Jack Schuler 58,254 58,254
2022-04-07	Jack Schuler has served as a Director of the company since June 26, 2012. ... The Board has affirmatively determined that directors ... Schuler ... are “independent directors” ... The Board maintains a standing Audit Committee comprised of Messrs. ten Brink (Chairman), Burris, Miller and Dr. Strobeck. ... The Board maintains a standing Nominating and Governance Committee comprised of Messrs. Miller (Chairman), Schuler and Dr. Watts. ... The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2021: Jack Schuler 140,799
2023-05-01	Jack Schuler has served as a Director of the company since June 26, 2012... The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2022: Jack Schuler 45,569